PMCH and melanoma: These resistance mechanisms include loss/downregulation of MCH complex, aberrant dynamics of signal transduction pathways (e.g., AKT/PKB, p38MAPK, JAK/STAT, PTEN, etc.), dysregulation of apoptotic machinery, etc. These mechanisms confer apoptosis resistance to melanomas despite the presence of a fully functional and effective antitumor immune response.